Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-30

Clinical Trial Update: Head to Head Study of Anti-VEGF Treatment. [Phase 4]

View source ↗

Summary

Phase 4 head-to-head trial of anti-VEGF treatment for age-related macular degeneration completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anti-VEGF therapy (head-to-head)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2017-11-30